Skip to content
Axe Capital logo Axe Capital Trading News

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

2026-10-09 14:30 •Prosper Junior Bakiny •The Motley Fool Positive Axe Cap view: Selective •Equities•Earnings•M&A•Capital Returns•Healthcare •ABBV•AMGN•ABT

Axe Cap view

Positioning for the Next Downturn: A Local Take on Defensive Stocks

With recession fears rising globally, South African investors should consider defensive sectors and monitor the rand closely.

Some economists warn of a market crash by 2027. While this might seem distant, it’s wise to look at sectors with steady cash flows and reliable dividends. Globally, big pharma stocks like AbbVie and Amgen are seen as safe havens because chronic disease treatments don’t stop even in recessions, supporting consistent earnings and dividends. On the JSE, we don’t have exact equivalents, but banks like Standard Bank and FirstRand tend to yield solid dividends and have weathered economic cycles better than industrials or retailers, which are more sensitive to consumer spending. The rand’s outlook will also shape performance: a weaker USD/ZAR could support exporters but hurt importers and banks with foreign currency exposure. If the market’s timing is off and growth continues beyond 2027, defensive positioning could lag. But prudence suggests trimming cyclical exposure and adding dividend-rich companies now. this is just our opinion and not financial advice

How I would invest

Trim exposure to highly cyclical JSE stocks and increase allocations in dividend-focused banks like Standard Bank and FirstRand. Watch USD/ZAR movements closely to time opportunistic buys in exporters.

What I would watch
  • Standard Bank
  • FirstRand
  • USD/ZAR
What could go wrong
  • Recession delayed beyond 2027
  • Rand strength undermining defensive exporters
How strongly I feel

6/10

Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.

Our take is based on reporting first published by The Motley Fool.

Read the original story